Page last updated: 2024-12-07

cgp 28392

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

CGP 28392: partial calcium channel agonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123861
CHEMBL ID2151429
CHEBI ID34600
SCHEMBL ID9178940
MeSH IDM0120646

Synonyms (30)

Synonym
ciba 28392
cgp 28392
cgp-28392
furo-(3,4-b)pyridine-3-carboxylic acid, 4-(2-(difluoromethoxy)phenyl)-1,4,5,7-tetrahydro-2-methyl-5-oxo-, ethyl ester
furo(3,4-b)pyridine-3-carboxylic acid, 1,4,5,7-tetrahydro-4-(2-(difluoromethoxy)phenyl)-2-methyl-5-oxo-, ethyl ester
brn 4273004
ios 2456
furo(3,4-b)pyridine-3-carboxylic acid, 4-(2-(difluoromethoxy)phenyl)-1,4,5,7-tetrahydro-2-methyl-5-oxo-, ethyl ester
cgp 28-392
cgp 28 392
ethyl 4-[2-(difluoromethoxy)phenyl]-2-methyl-5-oxo-4,7-dihydro-1h-furo[3,4-b]pyridine-3-carboxylate
89289-93-0
ethyl 4-[2-(difluoromethoxy)phenyl]-2-methyl-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylate
CHEMBL2151429
chebi:34600 ,
7qhr316fga ,
unii-7qhr316fga
SCHEMBL9178940
cgp-28392, (+/-)-
ciba-28392
(+/-)-cgp 28392
rs 71684
rs-71684
ios-2456
4-[2-(difluoromethoxy)phenyl]-1,4,5,7-tetrahydro-2-methyl-5-oxo-furo[3,4-b]pyridine-3-carboxylic acid ethylester
Q27116172
DTXSID001008744
cbpbjkqtvkfooq-uhfffaoysa-n
furo[3,4-b]pyridine-3-carboxylic acid, 4-[2-(difluoromethoxy)phenyl]-1,4,5,7-tetrahydro-2-methyl-5-oxo-, ethyl ester
AKOS040746688

Research Excerpts

Overview

CGP 28392 is a recently described dihydropyridine derivative with positive inotropic properties.

ExcerptReferenceRelevance
"CGP 28392 is a recently described dihydropyridine derivative with positive inotropic properties. "( Inotropic effect, binding properties, and calcium flux effects of the calcium channel agonist CGP 28392 in intact cultured embryonic chick ventricular cells.
Kim, D; Laurent, S; Marsh, JD; Smith, TW, 1985
)
1.93

Dosage Studied

ExcerptRelevanceReference
" In the isolated rat mesenteric artery, perfused with a depolarizing solution, vasoconstrictor Ca2+ dose-response curves are shifted to the right by nifedipine."( In vitro comparative studies of the calcium-entry activators YC-170, CGP 28392, and BAY K 8644.
Criscione, L; Meier, M; Rogg, H; Truog, A, 1985
)
0.5
" Bay K 8644 caused a leftward shift of the dose-response curve of the potassium-induced decrease in renin release."( Inhibitory effects of calcium channel agonists on renin release from rat kidney cortical slices.
Matsumura, Y; Morimoto, S; Sasaki, Y; Shinyama, H; Uriu, T, 1987
)
0.27
" The 45Ca++ uptake dose-response curves and the half maximal effects of the three agonists were over the same range of concentrations as their inhibition of [3H]nitrendipine binding to rat ventricular receptor membrane preparations."( Calcium uptake studies of 1,4-dihydropyridine agonists into rabbit aortic smooth muscle cells in culture.
Panzer-Knodle, S; Papaioannou, S; Yang, PC, 1989
)
0.28
" Dose-response curves for the physiological effects of the drugs are observed over the same range of concentrations as their inhibition of [3H]nitrendipine binding to its receptor."( Activation of the voltage-dependent Ca2+ channel in rat heart cells by dihydropyridine derivatives.
Lazdunski, M; Méaux, JP; Renaud, JF; Romey, G; Schmid, A, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID690060Vasodilatory activity in human vena saphena magna assessed as reduction in phenylephrine-induced smooth muscle contraction at 100 uM relative to baseline contraction2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690062Vasodilatory activity in human vena saphena magna assessed as reduction in phenylephrine-induced smooth muscle contraction at 0.1 uM2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
AID690063Vasodilatory activity in human vena saphena magna assessed as relaxation of phenylephrine-induced smooth muscle contraction at 10'-7 to 10'-4 M2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Effect of 4-aryl-2-methyl-5-nitro-1,4-dihydropyridine-3-carboxylates on the guinea pig papillary muscle and isolated human vena saphena magna that is used for coronary artery bypass grafting.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (72)

TimeframeStudies, This Drug (%)All Drugs %
pre-199050 (69.44)18.7374
1990's19 (26.39)18.2507
2000's1 (1.39)29.6817
2010's2 (2.78)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.32%)5.53%
Reviews3 (3.95%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other72 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]